Welcome to our dedicated page for Profusa SEC filings (Ticker: PFSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Profusa, Inc. (Nasdaq: PFSA) SEC filings page provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. Profusa is a commercial stage digital health and medical technology company focused on tissue-integrated biosensors and its Lumee Oxygen tissue monitoring platform, and its filings offer detailed insight into its capital structure, governance, financing arrangements and listing status.
Through this page, users can review current reports on Form 8-K where Profusa discloses material events such as securities purchase agreement amendments, senior secured convertible promissory note modifications, equity line of credit approvals, Nasdaq listing notifications, and manufacturing or commercial milestones referenced in Regulation FD disclosures. These 8-K filings explain key terms of convertible notes, floor price adjustments, tranche structures and mandatory prepayment provisions tied to equity line proceeds.
Investors can also access proxy statements on Schedule 14A, which describe special meetings of stockholders convened to approve items such as potential issuance of more than 19.99% of outstanding shares upon conversion of senior secured convertible notes, increases in authorized common shares, and proposals authorizing the board to implement one or more reverse stock splits within a specified ratio range. These documents outline the board’s recommendations, voting requirements and the rationale behind each corporate action.
Additional filings include registration statements on Form S-1 and related amendments, which detail resale registrations for shares issuable upon conversion of Profusa’s notes, as well as the company’s status as an emerging growth company and smaller reporting company. Notifications of late filing on Form 12b-25 explain timing for quarterly reports when additional time is needed to finalize disclosures.
On Stock Titan, each Profusa filing is accompanied by AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand complex financing terms, proposed charter amendments, or Nasdaq compliance updates. Real-time integration with EDGAR ensures that new 8-Ks, S-1 amendments, proxy statements and other PFSA filings appear promptly, while insider transaction reports on Form 4 and periodic reports such as 10-K and 10-Q (when filed) can be browsed and compared over time.
This page is designed to help investors, analysts and other interested readers interpret Profusa’s regulatory disclosures around its Lumee biosensor platform, capital-raising activities, authorized share changes and potential reverse stock splits using concise AI explanations alongside the full official documents.
Profusa, Inc. (PFSA) reports that stockholders approved an amendment to its Amended and Restated Certificate of Incorporation authorizing the board to implement, at its discretion, one or more reverse stock splits of the company’s common stock over the next two years, at ratios ranging from 1-for-2 to 1-for-12, with aggregate splits not exceeding 1-for-12. As of the August 19, 2026 record date, 605,647 common shares were outstanding, and a quorum of 287,890 shares was represented at the special meeting. Stockholders also approved the proposal allowing adjournment of the meeting if additional proxies are needed, but no other actions were taken and no specific reverse split ratio or effective date has yet been set.
Profusa, Inc. (PFSA) disclosed that on September 16, 2026 it completed an additional closing under its February 11, 2025 Securities Purchase Agreement and issued Ascent Partners Fund LLC a Senior Secured Convertible Promissory Note with aggregate principal of $384,615.38 for a purchase price of $350,000.00, reflecting original issue discount.
The Note is secured, is convertible, and matures on the earlier of September 16, 2027 or the Option Closing Date defined in the Note. This transaction creates a new direct financial obligation of Profusa under a senior secured convertible debt instrument.
Profusa, Inc. (PFSA) announced that Nasdaq has confirmed the company has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the Bid Price Rule) and Listing Rule 5550(b)(1) (the Equity Rule, together the Listing Rules) as of the Compliance Determination Letter dated September 9, 2026.
The company will, however, be subject to a one-year Mandatory Panel Monitor
The company states that it intends to continue monitoring compliance with all Nasdaq continued listing requirements. Profusa also notes it previously signed an Option Agreement giving it the right, subject to conditions, to acquire G3 Vision Labs, Inc., after which the combined company is expected to operate as a public diagnostics company if the option is exercised.
Profusa, Inc. (PFSA) reports that Chief Financial Officer Fred S. Knechtel had his ownership restructured on August 21, 2026 through entity transactions. He acquired 54,323 shares of common stock directly via a pro rata distribution from NorthView Sponsor I LLC and no price was paid.
The filing also shows the disposition of 301,991 indirectly held shares previously held through NorthView Sponsor I LLC, which distributed all its Profusa shares to its members. After these transactions, Knechtel directly holds 54,470 shares of Profusa common stock, including 147 shares he already held, and no Rule 10b5-1 trading plan is reported.
Profusa, Inc. (PFSA) reported that Chief Executive Officer Jack E. Stover restructured his holdings in the company’s common stock on August 21, 2026. He received 32,018 shares directly through a pro rata distribution from NorthView Sponsor I LLC, bringing his direct holdings to 32,091 shares, including 73 shares already held. On the same date, 301,991 indirectly held shares attributed to NorthView Sponsor I LLC were distributed to its members, leaving no remaining indirect holdings for Stover through that LLC. The filing notes that Stover is a manager of the LLC and may be deemed to share beneficial ownership of its securities but disclaims beneficial ownership except to the extent of his pecuniary interest. No Rule 10b5-1 trading plan is reported for these transactions.
Profusa, Inc. (PFSA) entered into a financing transaction by completing an additional closing under its existing Securities Purchase Agreement with Ascent Partners Fund LLC. Profusa issued Ascent a Senior Secured Convertible Promissory Note with an aggregate principal amount of $329,670.33 for an aggregate purchase price of $300,000.00, reflecting original issue discount. The note is senior, secured and convertible, and it matures on the earlier of September 1, 2027 or the Option Closing Date defined in the note. This creates a new direct financial obligation for Profusa, with potential future equity conversion depending on the note’s terms.
Profusa, Inc. (PFSA) reported that Nasdaq’s Listing Qualifications Department notified the company that, after its recent 1-for-4 reverse stock split, it initially appeared to have fewer than the 500,000 publicly held shares required by Nasdaq Listing Rule 5550(a)(4). After Profusa’s correspondence with Nasdaq on August 21, 2026, Nasdaq determined that Profusa is in compliance with this publicly held shares requirement and has closed its review, with no further action required. Trading of Profusa’s common stock continues on Nasdaq under the symbol PFSA. Profusa states that it will continue monitoring compliance with all Nasdaq continued listing standards and highlights ongoing uncertainty around separate Nasdaq requirements such as the Bid Price, MVLS, and MVPHS rules in its forward-looking statements.
Profusa, Inc. (PFSA) is calling a virtual special stockholders’ meeting on September 18, 2026 to vote on two proposals. The main item would authorize the Board, at its discretion, to implement one or more reverse stock splits of the common stock, at ratios ranging from 1-for-2 to 1-for-12 in total, at any time up to September 18, 2028, without further stockholder approval. As of the August 19, 2026 record date, 605,647 shares of common stock were outstanding.
The Board cites continued listing on Nasdaq’s Capital Market, including compliance with the $1.00 minimum bid price, improved liquidity, and better access to financing (including shelf and equity-line facilities) as key reasons for this authority. The company discloses multiple prior reverse splits in 2026 (including a 1-for-4 split on August 17, 2026) used in efforts to satisfy Nasdaq requirements and notes that failure to maintain listing could severely limit liquidity and capital-raising options. A secondary proposal would permit adjournment of the meeting to solicit more proxies if needed.
Profusa, Inc. (symbol: PFSA) is the issuer of record for a Form 8-K filing submitted to the SEC.
Profusa, Inc. (PFSA) reported progress on its capital structure and its previously signed Option Agreement to acquire G3 Vision Labs, Inc. Debt and liability holders executed $10.7 million of Series A Convertible Exchange Agreements, with $4.57 million converted into Series A Convertible Preferred Stock, and the company states it has sufficient working capital to fund near‑term operations.
Profusa expects PCAOB‑audited 2024 and 2025 financial statements for G3 and its subsidiaries by mid‑September, a key condition to potentially exercising the option to acquire G3 and operate as a public diagnostics company with national CLIA‑certified laboratories and recurring revenues. Profusa also completed a reverse stock split and released its financial results for the quarter ended June 30, 2026.